Voyager Therapeutics, Inc. Forecast, price target & analysts
Voyager Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Voyager Therapeutics, Inc. Classifications & Recommendation:
Voyager Therapeutics, Inc. Price Target
| Target Price | $16.10 |
| Price | $3.53 |
| Potential |
356.09%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Voyager Therapeutics, Inc. 2026 .
The average Voyager Therapeutics, Inc. target price is $16.10.
This is
356.09%
register free of charge
$30.00
749.86%
register free of charge
$9.00
154.96%
register free of charge
|
|
| A rating was issued by 12 analysts: 12 Analysts recommend Voyager Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Voyager Therapeutics, Inc. stock has an average upside potential 2026 of
356.09%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 80.00 | 66.14 |
| 68.00% | 17.32% | |
| EBITDA Margin | -98.20% | -160.68% |
| 294.14% | 63.63% | |
| Net Margin | -77.31% | -138.47% |
| 218.90% | 79.12% |
12 Analysts have issued a sales forecast Voyager Therapeutics, Inc. 2025 . The average Voyager Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Voyager Therapeutics, Inc. EBITDA forecast 2025. The average Voyager Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Voyager Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Voyager Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.13 | -1.67 |
| 138.05% | 47.79% | |
| P/E | negative | |
| EV/Sales | negative |
12 Analysts have issued a Voyager Therapeutics, Inc. forecast for earnings per share. The average Voyager Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Voyager Therapeutics, Inc....
Current Voyager Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
